Response

Number of mice (total n=80) Percentage
Complete regression on both sides (Responders)
45%
Did not respond on any side (Non-Responders) 33 41.25%
Responded on one side (Mixed Responders) 11 13.75% Supplementary Table 1 . Symmetry of response of bilaterally inoculated AB1-HA tumours. Mice were injected with 1 x 10 6 AB1-HA cells on day 0 and treated with anti-CTLA4 100 -200 µg on day 5 or 6. Pooled results from 5 independent experiments are shown. Note that the mice that displayed a progressing lesion on one side, always did so before day 40 after tumour inoculation (Fig. 1b in article) ; by observing tumour growth of the indicator tumour for longer than that period, we could thus further decrease the possibility of resecting a non-symmetric responding tumour. Supplementary Fig. 1 . Differential expression of the modules in (a) responders versus untreated and (b) non-responders versus untreated. Although module 8 was differentially expressed comparing responders with non-responders ( Fig. 2c in article) , it was also strongly upregulated in tumors from nonresponders compared to PBS controls (in c). Modules 2 and 4 were not differentially expressed when comparing nonresponders with untreated (in b), while it was significantly different between responders and untreated (in a) and responders and non-responders ( Fig. 2c in article) . Therefore, modules 2 and 4 were most differentially expressed between responders and nonresponders. Supplementary Table 4 . Identification of drug repurposing candidates that can promote treatment response using the cMap build 02 database. The database was queried with a gene signature derived from the immune and cancer modules. Mean represents the arithmetic mean of the connectivity scores, which are defined as the strength of the overlap between the perturbation signature in cMap with the gene expression signature in the immune/cancer modules, over the set of experiments for that drug and cell line (n). The enrichment is a measure of the enrichment of those experiments amongst a ranked list of all experiments. P is a permutation p-value for the enrichment. Specificity is a measure of the uniqueness of the connectivity in comparison to experimentallyderived signatures from MSigDB (high values indicate low specificity). Supplementary Table 5 . Prior knowledge based identification of drugs that are predicted to promote treatment response. Upstream regulator analysis (Ingenuity Systems) was employed to identify drugs that based on experimental findings reported in the literature are known to regulate expression levels of genes in the immune/cancer modules. The overlap p-value is based on enrichment of genes whose expression levels are known to be modulated by a given drug. The activation Z-score is a measure of the pattern match between the direction of the gene expression changes (up/down regulation) and the predicable pattern from prior knowledge. A"
treated with anti-CTLA4 (100 µg on day 10) in combination with therapeutics targeted at specific response-associated hubs (a-e, also see Fig. 3 in the article) or drugs based on overlap with drug-perturbation signatures in the cMap database 1 (f-i, also see Fig. 4 in the article). (a-c) Recombinant murine cytokines IL-12, IL-18, IFNγ and IL-1β were used, since they were all hubs within the immune module and upregulated in responders (a representative of two independent experiments with n = 5-10 mice per arm is shown; for clarity the experiment is divided over three separate graphs). No significant differences were observed. (d) We observed that several hub genes in the cancer module were involved in Rho kinase activation, and were downregulated in responders only. For this reason, we treated mice with anti-CTLA4 in combination with fasudil, a Rho kinase-specific inhibitor that is used in patients with cerebral vasospasm 2 (two separate experiments are combined in this graph, n = 20 mice per arm for anti-CTLA4-containing regimes, n = 8 for control arms). Fasudil alone did not result in any growth delay, but in combination with anti-CTLA4 it increased the response rate consistently in several independent experiments, however without reaching statistical significance. This is partly explained by the overlapping curves in the beginning of the curve, as a result of increasing the response rates without affecting survival in all mice 3 . Since the difference in survival did not reach statistical significance after treating 20 mice per arm, we did not continue testing this drug. (e) CDKN1 inhibitor flavopiridol was tested in combination with anti-CTLA4 since CDKN1 was a hub within the cancer module, which was downregulated in responders. The outcome after combination treatment was significantly worse than after anti-CTLA4 alone. This can be explained by negative effects on lymphocyte responses, and thus the immune model, as has been reported before by others 4 . This formed an important reason for us to investigate whether we could use pleiotropic drugs that would target the immune and cancer module at the same time, based on an overlap in drug-perturbation signatures in the cMap database and the gene expression in our dataset of genes with in the immune and cancer module, as described in the article. We identified several drug candidates in this manner (see also Fig. 4 in the article), including (f) Alzheimer's drug Galantamine (a representative of two independent experiments, n = 10 mice for anti-CTLA4-containing regimes, n = 5 for control arms), (g) vitamine B/Pyridoxine (two separate experiments are combined in this graph, n = 20 mice per arm for anti-CTLA4-containing regimes, n = 13 for pyridoxine and 6 for PBS arms), (h) analgesic Hydrocotamine (a representative of two independent experiments, n = 10 mice for anti-CTLA4-containing regimes, n = 5 for control arms) and (i) plant alkaloid Tomatidine (one experiments, n = 10 mice for anti-CTLA4-containing regimes, n = 5 for control arms). Although again for some of these drugs we indeed consistently observed over multiple experiments that response rates were increased, this did not translate in a significant difference in overall survival.
